Its clinical significance has been extensively demonstrated in chronic heart failure, particularly heart failure with HFpEF, where elevated serum galectin-3 levels predict new-onset disease, adverse outcomes including all-cause death and cardiovascular death, and correlate with the severity of left ventricular diastolic dysfunction and cardiac structural abnormalities (134, 135). The gene discussed is LGALS3; the disease is heart failure.